Travere Therapeutics
TVTX
114 hedge funds and large institutions have $753M invested in Travere Therapeutics in 2017 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 48 reducing their positions, and 16 closing their positions.
546% more call options, than puts
Call options by funds: $7.43M | Put options by funds: $1.15M
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
0.55% less ownership
Funds ownership: 107.71% → 107.17% (-0.55%)
2% less capital invested
Capital invested by funds: $769M → $753M (-$16M)
6% less funds holding
Funds holding: 121 → 114 (-7)
19% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 48
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$61.1M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$15.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$10.5M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$8.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$12.5M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$7.83M |
| 3 |
BC
Broadfin Capital
New York
|
-$7.38M |
| 4 |
Jennison Associates
New York
|
-$5.62M |
| 5 |
Millennium Management
New York
|
-$4.86M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Squarepoint
New York
| – | -$235K | -12,428 | Closed |
|
|
MPAM
127
Monarch Partners Asset Management
Boston,
Massachusetts
| – | -$223K | -11,760 | Closed |
|
|
TRCT
128
Tower Research Capital (TRC)
New York
| – | -$27K | -1,426 | Closed |
|
TVTX Hedge Fund Activity: Q1 2017 in Review
114 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2017, worth a combined $753M — down 2.1% from $769M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TVTX positions and 16 closed out — a net gain of 1 holder — while 39 added to existing stakes and 48 trimmed.
The largest buyer was BlackRock, adding an estimated $61.1M. The largest seller was Consonance Capital Management, cutting an estimated $12.5M.
- 114 institutional investors held Travere Therapeutics (TVTX) as of Q1 2017, down from 121 in Q4 2016.
- Funds reported $753M of Travere Therapeutics stock for Q1 2017, down 2.1% quarter-over-quarter.
- 17 funds opened new Travere Therapeutics positions in Q1 2017 and 16 closed out, a net change of +1 holder.
- The largest Travere Therapeutics buyer in Q1 2017 was BlackRock, an estimated $61.1M added.
- The largest Travere Therapeutics seller in Q1 2017 was Consonance Capital Management, an estimated $12.5M sold.
Based on aggregated 13F filings for Q1 2017.